Skip to main content

Table 3 Potential new ductal carcinoma in situ susceptibility loci

From: Genetic predisposition to ductal carcinoma in situ of the breast

Single nucleotide polymorphism

rs12631593

rs13236351

rs73179023

Chromosome

3

7

22

Position

60701884

97772513

43424477

Locus

FHIT

LMTK2

PACSIN2:TTLL1

Minor allele frequency

0.11

0.032

0.13

ICICLE DCIS phase I

  

Odds ratio (95 % CI)

1.15 (1.04, 1.28)

1.31 (1.10, 1.56)

0.83 (0.75, 0.91)

P

0.0088

0.0029

0.00020

BCAC DCIS

  

Odds ratio (95 % CI)

1.25 (1.14, 1.36)

1.3 (1.12, 1.51)

0.86 (0.79, 0.94)

P

1.0 × 10-6

0.00060

0.0012

Meta-analysis phase I

  

Odds ratio (95 % CI)

1.21 (1.13, 1.29)

1.3 (1.16, 1.46)

0.85 (0.79, 0.90)

P

5.5 × 10-8

5.7 × 10-6

1.1 × 10-6

Phase II DCIS

  

Odds ratio (95 % CI)

0.93 (0.76, 1.14)

0.91 (0.63, 1.31)

0.95 (0.78, 1.15)

P

0.49

0.61

0.57

Meta-analysis phase II

  

Odds ratio (95 % CI)

1.18 (1.10, 1.25)

1.26 (1.13, 1.41)

0.86 (0.80, 0.91)

P

7.8 × 10-7

2.9 × 10-5

1.7 × 10-6

BCAC IDC

  

Odds ratio (95 % CI)

1.01 (0.97, 1.05)

1.05 (0.99, 1.13)

0.97 (0.93, 1.00)

P

0.54

0.13

0.060

Case-only

  

DCIS vs IDC P-Het

0.0048

0.17

0.0099

  1. DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, BCAC Breast Cancer Association Consortium, ICICLE Study to investigate the genetics of in situ carcinoma of the ductal subtype, P-Het P value for heterogeneity